Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDA
Protocol revisions agreed to by the FDA include the use of peripheral blast burden as an inclusion criteria, the mandated use of Hydroxyurea in patients with high peripheral blast burden and the elimination of low dose cytarabine
Trial will enroll 53 patients in a multicenter, open-label study designed to evaluate patient complete response rates and overall survival

NEW YORK - September 27, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program consists of the CD33 targeting monoclonal antibody, HuM195, and the alpha-emitting radioisotope, actinium-225.

Revolutionary intelligent deep fiber access node collapses access and service edge functions into a distributed network architecture eliminating up to 80 percent of headend and central office facilities and associated OPEX

PHILADELPHIA – September 27, 2016 –Calix, Inc. (NYSE: CALX), the world leader in subscriber driven access, today introduced the AXOS E3-2 Intelligent PON Node, a revolutionary system designed to collapse access and service edge functions into a distributed network architecture, disrupting the economics of driving PON technology into a fiber deep architecture and dramatically reducing service provider operational costs. Featuring an environmentally hardened, modular “deploy anywhere design” that can be mounted aerially, on a pole, on a wall, or in a pedestal, the E3-2 is fully upgradable and serviceable, enabling rapid upgrades to 10 gigabits per second (10 Gbps) and higher speed PON technologies in the future.

Black Swan Event: An unpredictable or unforeseen event, typically one with extreme consequences

Deutsche Bank AG (NYSE:DB) may be the black swan no one is talking about. The European bank opened below a major triple bottom support level at new lows. It has been widely said, that if that triple bottom support level broke, it would cause Deutsche Bank to spin out of control and into default.

An event such as this would trigger a domino effect among other financial institutions, mainly in Europe but would send ripples through U.S. banks as well. It would likely cause a major economic event. A Lehman type collapse and catastrophic event is possible.

There is one simple reason why I am buying the 3x long biotech ETF $LABU into the stock market close today. There is a Presidential Debate tonight and biotech has been under pressure the last few trading days, afraid of what targeted attacks it would get from the candidates. Ultimately, there will be relief when it is over, not matter what is said. The fear of what may be said is always worse than the actual event, which means a sharp biotechnology rally tomorrow. This is literally a 1-3 day swing trade. Quick in and quick out. I am aiming to maxmize gains as much as possible, thus the plans to buy $LABU.